Metformin increases efficacy of everolimus-letrozole combo for EEC
June 17, 2016|Ob.Gyn. News
Author and Disclosure Information
AT THE 2016 ASCO ANNUAL MEETING
“This trial has recently completed accrual and results are pending. This will allow us to better identify how this treatment strategy compares to hormonal therapy alone in women with recurrent endometrial cancer. In addition, at our institution we are investigating other agents to be added to the everolimus and letrozole backbone to enhance response to patients with endometrioid endometrial cancer,” she said.
Dr. Soliman reported receiving research funding (to her institution) from Novartis.
